Analysis of Bevacizumab Treatment Practices, Survival and Quality of Life Outcomes in Recurrent Glioblastoma Patients
This Canadian cohort analysis characterizes bevacizumab treatment practices, survival and quality of life outcomes in rGBM patients in BC. Further investigations are needed to identify the demographic and biomarker characteristics of rGBM patients who would most benefit from bevacizumab treatment.
Authors
- Katherine K. Preston
- Brian Thiessen (ORCID: https://orcid.org/0000-0003-0752-6673)
- Manik Chahal (ORCID: https://orcid.org/0000-0002-8862-2028)
- R. C. Harrison (ORCID: https://orcid.org/0000-0001-8355-2406)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- Canadian Centre for Applied Research in Cancer Control (CA)
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1017/cjn.2025.10457
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00